HBW Advisory Services LLC Purchases 2,611 Shares of Amgen Inc. $AMGN

HBW Advisory Services LLC boosted its position in shares of Amgen Inc. (NASDAQ:AMGN) by 122.3% during the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 4,746 shares of the medical research company’s stock after acquiring an additional 2,611 shares during the period. HBW Advisory Services LLC’s holdings in Amgen were worth $2,001,000 at the end of the most recent quarter.

Several other large investors have also recently added to or reduced their stakes in AMGN. State Street Corp grew its holdings in shares of Amgen by 38.2% during the 2nd quarter. State Street Corp now owns 42,205,243 shares of the medical research company’s stock worth $15,283,363,000 after purchasing an additional 11,656,755 shares in the last quarter. Bank of America Corp DE acquired a new position in shares of Amgen in the second quarter valued at $1,831,903,000. Wellington Management Group LLP raised its stake in shares of Amgen by 1,102.7% in the second quarter. Wellington Management Group LLP now owns 2,742,271 shares of the medical research company’s stock valued at $993,031,000 after purchasing an additional 2,514,254 shares in the last quarter. BlackRock Inc. lifted its position in Amgen by 4.8% in the second quarter. BlackRock Inc. now owns 49,362,016 shares of the medical research company’s stock worth $17,874,974,000 after purchasing an additional 2,261,544 shares during the period. Finally, Corient Private Wealth LP bought a new position in Amgen in the second quarter worth $187,401,000. Institutional investors and hedge funds own 76.50% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts have weighed in on the stock. Guggenheim decreased their price target on shares of Amgen from $388.00 to $378.00 and set a “neutral” rating on the stock in a research note on Tuesday. UBS Group boosted their price target on shares of Amgen from $430.00 to $470.00 and gave the company a “buy” rating in a report on Friday, October 9th. Oppenheimer restated an “outperform” rating on shares of Amgen in a research note on Wednesday, September 23rd. Royal Bank Of Canada raised their price objective on shares of Amgen from $400.00 to $430.00 and gave the stock an “outperform” rating in a report on Thursday, October 8th. Finally, Citigroup lifted their target price on shares of Amgen from $345.00 to $405.00 and gave the company a “neutral” rating in a research report on Friday, August 7th. One equities research analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, sixteen have issued a Hold rating and three have assigned a Sell rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $387.93.

Amgen Price Performance

Shares of AMGN stock opened at $426.11 on Thursday. The stock’s fifty day simple moving average is $414.53 and its 200 day simple moving average is $373.75. Amgen Inc. has a one year low of $288.00 and a one year high of $447.03. The firm has a market cap of $230.37 billion, a price-to-earnings ratio of 26.48, a P/E/G ratio of 3.02 and a beta of 0.41. The company has a debt-to-equity ratio of 4.44, a current ratio of 1.37 and a quick ratio of 1.13.

Amgen (NASDAQ:AMGN) last released its quarterly earnings data on Tuesday, August 4th. The medical research company reported $6.29 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.62 by $0.67. Amgen had a return on equity of 124.14% and a net margin of 22.95%. The firm had revenue of $10.05 billion during the quarter, compared to analyst estimates of $9.43 billion. During the same period in the prior year, the company posted $6.02 earnings per share. The business’s revenue for the quarter was up 9.5% compared to the same quarter last year. Amgen has set its FY 2026 guidance at 22.300-23.500 EPS. On average, analysts expect that Amgen Inc. will post 22.94 earnings per share for the current fiscal year.

Amgen Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Friday, September 11th. Stockholders of record on Friday, August 21st were paid a $2.52 dividend. This represents a $10.08 annualized dividend and a dividend yield of 2.4%. The ex-dividend date was Friday, August 21st. Amgen’s payout ratio is currently 62.65%.

Insider Activity

In other news, SVP Nancy Grygiel sold 2,970 shares of the company’s stock in a transaction dated Thursday, August 6th. The shares were sold at an average price of $402.16, for a total value of $1,194,415.20. Following the sale, the senior vice president owned 7,340 shares of the company’s stock, valued at approximately $2,951,854.40. This represents a 28.81% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, SVP Rachna Khosla sold 1,252 shares of the stock in a transaction dated Thursday, August 13th. The stock was sold at an average price of $416.43, for a total transaction of $521,370.36. Following the sale, the senior vice president owned 6,404 shares of the company’s stock, valued at $2,666,817.72. This trade represents a 16.35% decrease in their position. The SEC filing for this sale provides additional information. In the last ninety days, insiders sold 6,222 shares of company stock worth $2,540,926. 0.85% of the stock is owned by insiders.

Amgen News Summary

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Amgen and AstraZeneca reported positive Phase 3 results for Tezspire in eosinophilic esophagitis. Nearly 70% of patients receiving the higher dose achieved remission after 24 weeks, strengthening the drug’s expansion opportunity in a condition with limited approved treatments. What Could Amgen (AMGN) 70% Remission Trial Result Mean For Its Pipeline?
• Positive Sentiment: UBS raised its price target for Amgen to $470, signaling increased confidence in the company’s earnings and pipeline outlook. Cantor Fitzgerald also recently lifted its target to $440. UBS raises target for Amgen stock to USD 470.00 Cantor Fitzgerald raised target for Amgen stock to USD 440
• Positive Sentiment: Investors are also focusing on Amgen’s broader growth prospects, including planned Phase 3 studies for obesity drug candidate MariTide, continued manufacturing investment, and the European Union authorization of Jascayd. These developments reinforce expectations for future product launches and portfolio expansion. Amgen Gains as Investors Appear to Lean on Pipeline and Regulatory Momentum
• Positive Sentiment: Erste Group raised its FY2027 earnings-per-share estimate to $24.66 from $24.36, above Amgen’s current-year consensus estimate of $22.94. The revision suggests some analysts expect continued earnings growth.
• Neutral Sentiment: A new Phase 1 study is evaluating an alternative delivery approach for Evenity. The study could support product optimization, but it is early-stage and unlikely to materially affect near-term results. Amgen Fine-Tunes Evenity Delivery in New Phase 1 Study
• Negative Sentiment: Bank of America Securities continues to rate Amgen a Sell, providing a counterweight to the recent target increases and highlighting continued valuation or execution concerns. Bank of America Securities Remains a Sell on Amgen
• Negative Sentiment: Amgen insiders reported seven open-market sales and no purchases over the past six months. While these transactions are not necessarily company-specific signals, the absence of insider buying may temper bullish sentiment.

About Amgen

Amgen Inc is a biotechnology company that discovers, develops, manufactures and delivers medicines for serious illnesses. Its research and commercial activities focus on areas including oncology, cardiovascular disease, inflammation, bone health, neuroscience and rare diseases. The company uses biologic research, human genetics and other advanced technologies to develop targeted therapies and supports patients through treatment and disease-management services.

Amgen’s portfolio includes medicines such as Enbrel for inflammatory diseases; Prolia and Evenity for osteoporosis; Xgeva for cancer-related bone complications; Repatha for certain cardiovascular conditions; Otezla for inflammatory diseases; Aimovig for migraine prevention; Tezspire for severe asthma; and Lumakras for certain cancers.